PharmaShots Weekly Snapshot ( February 11-15, 2019)
Published: 14 Feb,2019 | Tags: Arvelle Therapeutics, Licenses, Exclusive, Development, Commercialization, Rights, Cenobamate, SK Biopharmaceuticals, EU
2. Novartis Signs a Multi-Target Agreement with AbCellera for its Ab-Based Technology
Published: 14 Feb,2019 | Tags: Novartis, Signs, Multi-Target, Agreement, AbCellera, Ab-Based, Technology
Published: 14 Feb,2019 | Tags: Bristol-Myers, BMS, Reports, Results, Opdivo, nivolumab, Yervoy, ipilimumab, P-II, CheckMate -650 trial, Metastatic Castration-Resistant Prostate Cancer, mCRPC
Published: 14 Feb,2019 | Tags: Nestle Health Science,NHSc, Exercises, Exclusive, WorldWide, Option, License, CDX-6114, Codexis
Published: 15 Feb,2019 | Tags: Bayer, Reports, Results, Darolutamide, P-III, ARAMIS trial, Non-Metastatic Castration-Resistant Prostate Cancer, nmCRPC, ADT, Androgen Deprivation Therapy
Published: 13 Feb,2019 | Tags: Roche, Signs, Clinical Program, Agreement, Vaccibody,Evaluate, VB10.16 + Tecentriq, atezolizumab, Advanced Cervical Cancer, ACC
7. Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)
Published: 14 Feb,2019 | Tags: Amgen, Signs, Multi-Target, Collaboration, Abilita Bio, Enabled Membrane Proteins, EMPs
8. Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US
Published: 14 Feb,2019 | Tags: Clinigen, Licenses, Commercialization, Rights, Proleukin, Novartis, the US
9. Johnson & Johnson to Acquire Auris Health for its Monarch Technology for $5.7B
Published: 14 Feb,2019 | Tags: Johnson&Johnson, Acquire, Auris Health, Monarch Technology, $5.7B, Lung Cancer
10. Novartis Egaten (triclabendazole) Receives FDAs Approval for Fascioliasis in the US
Published: 14 Feb,2019 | Tags: Novartis, Egaten, triclabendazole, Receives, FDA, Approval, Fascioliasis, the US
Published: 13 Feb,2019 | Tags: ITROM Pharmaceutical, Signs, Exclusive, License, Commercialization, Agreement, Mithra, 20 years
Published: 13 Feb,2019 | Tags: Almirall, Signs, Option, License, Agreement, Dermira, Develop, Commercialize, Lebrikizumab, EU, Atopic Dermatitis
13. Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU
Published: 13 Feb,2019 | Tags: Bayer, Signs, Exclusive, License, Agreement, Moberg Pharma, MOB-015, EU
Published: 13 Feb,2019 | Tags: Janssen, J&J, Reports, Voting, Results, FDA, Advisory Committees, Spravato, esketamine,Adults, Resistant Depression
15. AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B
Published: 13 Feb,2019 | Tags: AbbVie, Signs, Partner, Option, Acquire, Agreement, Teneobio, TNB-383B
Published: 13 Feb,2019 | Tags: Gilead, Reports, Results, Selonsertib, P-III, STELLAR-4 study, Compensated Cirrhosis, F4, Nonalcoholic Steatohepatitis, NASH
Published: 13 Feb,2019 | Tags: Genmab, Darzalex, daratumumab, Split Dosing, Regimen, Receives, the US FDA, Approval, Multiple Myeloma
Published: 13 Feb,2019 | Tags: Takeda, Adcetris, brentuximab vedotin, AVD, Receives, EU Approval, CD30+, Stage, IV, Hodgkin Lymphoma, HL, Adults
Published: 13 Feb,2019 | Tags: Astellas, Reports, Results, Xtandi, enzalutamide, P-III, ARCHES Trial, Metastatic Hormone-Sensitive Prostate Cancer, mHSPC, Men
Published: 12 Feb,2019 | Tags: Bristol-Myers, Reports, Results, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate-214 study, Patients, Advanced, Metastatic, RCC
Published: 12 Feb,2019 | Tags: Finch Therapeutics, CP101, Receives, FDA, Breakthrough Therapy Designation, BT, Recurrent Clostridium difficile, C. difficile, Infection
Published: 12 Feb,2019 | Tags: Pfizer, Recalls, Lots, Ambaro, valsartan and amlodipine besylate salt, Carcinogenic, Effects, Japan
Published: 11 Feb,2019 | Tags: Regeneron, Reports, Results, Eylea, aflibercept, P-III, PANORAMA Trial, Diabetic Retinopathy, DR
Published: 11 Feb,2019 | Tags: C-Bridge, Capital, Signs, Development, Commercialization, Agreement, Samsung Bioepis, Biosimilars, China